Differences between Zepbound and Wegovy
There are several differences between how Zepbound and Wegovy work:
Zepbound
Zepbound works by mimicking two natural hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These help minimize hunger and regulate how the body processes sugar and fat. This dual action can lead to greater weight loss and improved blood sugar control.
Zepbound targets both hunger and metabolism. The combination of GLP-1 and GIP means that it not only limits appetite but also improves how the body manages nutrients, giving it a potential edge for more significant weight loss.
Zepbound has a flexible dosage that starts at 2.5 milligrams (mg) weekly. It can be increased to 15 mg, depending on individual needs and tolerance.
Wegovy
Wegovy works by mimicking just one hormone, GLP-1. It limits your appetite and increases feelings of fullness after eating, which helps control calorie intake and leads to weight loss over time. While it doesn't target GIP like Zepbound, it's highly effective for weight management.
Wegovy focuses primarily on hunger control. Its action on GLP-1 curbs appetite and promotes satiety, making it effective for those looking to manage their weight by eating less.
Wegovy starts at 0.25 mg weekly and gradually increases to 2.4 mg. The gradual dose increase helps minimize side effects while achieving effective weight loss.
Zepbound and Wegovy can both be used for those who are prediabetic or already have type 2 diabetes. However, when choosing between the two medications, you should consider your blood sugar status, since both can improve insulin sensitivity and A1C levels. Some tirzepatide formulations (the active ingredient found in Zepbound) are used for diabetes treatment.
If you've already been diagnosed with diabetes or prediabetes, it's especially important to talk through all health factors with your doctor before choosing a GP-1 medication. They can better help you understand your insulin resistance and which option is best for your lifestyle.
Eligibility for Zepbound vs. Wegovy
People in different body types with different health situations, goals and needs may find that one drug is better for them than the other. Ahead, find indication and eligibility differences for Zepbound and Wegovy.
To qualify for a Zepbound prescription, you must:
Be at least 18 years old
Have a Body Mass Index (BMI) of 30 or above or a BMI of 27 or higher with certain weight loss-related medical conditions (including hypertension, high cholesterol, type 2 diabetes or heart disease)
Have been diagnosed with Obstructive Sleep Apnea (OSA) and obesity
To receive a Wegovy prescription, you must:
Be at least 18 years old with a BMI of at least 30 or a BMI of 27-29 with at least one weight-related condition, such as hypertension, type 2 diabetes or high cholesterol
Adolescents aged 12 to 17 may qualify for Wegovy if their initial BMI is in the 95th percentile standardized for their age and sex
Effectiveness of Zepbound vs. Wegovy
Both Zepbound and Wegovy have been found to be effective for weight loss in obese and overweight individuals in conjunction with a reduced-calorie diet and a stepped-up exercise regimen. Here’s a breakdown of the effectiveness of each:
Zepbound has shown greater weight loss in clinical trials. In a 72-week trial, participants using the highest dose of Zepbound (15 mg) lost an average of 21% of their body weight. Nearly 55% (54.9%) of participants lost 20% or more of their body weight.
Wegovy led to significant weight loss but slightly less than Zepbound. In a 68-week trial, participants using Wegovy (2.4 mg) lost about 15% of their body weight.
These results tell us that Zepbound may be better for those seeking more aggressive weight loss, especially if previous treatments haven’t worked well.
The U.S. Food and Drug Administration (FDA) approved Wegovy in 2021 for weight loss among obese and overweight people. Then, in spring 2024, the FDA added another use, and now Wegovy is also used to reduce the threat of major adverse cardiovascular events (including heart attack, stroke and cardiovascular death) in those who are overweight or obese and have heart disease.
The FDA also approved Wegovy to treat metabolic-associated steatohepatitis (MASH), a serious liver disease, in adults with moderate to severe fibrosis.
Wegovy remains a strong contender for moderate weight loss, especially in those with heart disease. Even though Wegovy’s weight loss results are slightly lower than Zepbound’s, it has proven cardiovascular and liver benefits, making it a better fit for those with severe health concerns.
Both medications are administered as subcutaneous injections (beneath the skin) in the abdomen, thigh or upper arm. Since Zepbound and Wegovy are both injectable, they bypass the digestive system, leading to more consistent and effective results compared with oral weight loss medications.
Differences in active ingredients: Tirzepatide vs. semaglutide
| What it's approved for | What medications it's found in | Common side effects | Usage | |
|---|---|---|---|---|
| Tirzepatide | Type 2 diabetes, chronic weight management, obstructive sleep apnea | Mounjaro, Zepbound | Diarrhea, stomach pain | Single-dose prefilled pen, single-dose vial, multi-dose KwikPen, multi-dose vial |
| Semaglutide | Type 2 diabetes, cardiovascular health issues, chronic weight management, kidney disease and liver disease | Ozempic, Rybelsus, Wegovy | Belching, bloating, constipation, diarrhea, nausea | Injection shot via a prefilled pen, syringe or FlexTouch pen |
Zepbound vs. Wegovy cost comparison
There is no doubt that weight loss injections can be expensive. Without insurance, both Zepbound and Wegovy are very costly:
Zepbound generally costs $1,059.87 for a 30-day supply. This is the out-of-pocket price, but costs may be lower with insurance or manufacturer copay cards.
Wegovy costs can be about $1,349.02 per month. However, eligible patients may use copay cards to lower costs, with some paying as little as $0, depending on their insurance coverage.
Wegovy’s added cardiovascular benefits might make it a better overall investment for people who need both weight loss and heart disease management, even if it’s more expensive.
Neither medication is typically covered by Medicare for weight loss, though Wegovy may be covered for its cardiovascular benefits for those at risk for cardiovascular disease, making insurance a major factor in choosing the most cost-effective option.
Manufacturer copay programs can also reduce costs for both medications. Both Zepbound and Wegovy offer copay assistance, which can significantly reduce monthly expenses for those with commercial insurance.
Also, a new program from LillyDirect allows consumers to get Zepbound in 2.5 mg or 5 mg doses for $399 and $549 per month directly.
That being said, there have been drug shortages and issues with availability as GLP-1s have gained popularity in the past few years. It can be helpful to talk to your local pharmacy about medication availability before starting either injection. You can also research supply constraints and how they may have changed over time.
Healthcare professional opinions on Zepbound vs. Wegovy
Dr. Anastassia Amaro, the medical director of Penn Metabolic Medicine, has pointed out that both Zepbound and Wegovy are highly effective in reducing appetite and promoting satiety, but Zepbound — with its dual action on both GLP-1 and GIP hormones — may lead to slightly more significant weight loss compared with Wegovy.
For individuals considering these treatments and choosing between Zepbound and Wegovy, healthcare professionals advise evaluating personal health conditions, such as cardiovascular risks or blood sugar management needs.
Both medications require long-term use to maintain weight loss, and experts recommend incorporating lifestyle changes like resistance training and a balanced diet to optimize outcomes.
Zepbound vs. Wegovy side effects and safety
Common side effects for both Zepbound and Wegovy include gastrointestinal issues such as:
Nausea
Vomiting
Diarrhea
These side effects are often seen early in treatment and may lessen as the body adjusts to the medication. According to Dr. Amaro, tirzepatide (Zepbound) tends to be better tolerated in terms of nausea, which might make it more appealing for patients sensitive to this side effect.
Gallbladder issues and rapid weight loss can pose risks for both medications as well, as rapid weight loss may increase the risk of gallbladder problems. Guidance for managing side effects includes dose adjustments and monitoring.
Healthcare professionals like Amaro recommend starting at a lower dose and gradually increasing it to help manage side effects. Patients are encouraged to keep an open line of communication with their doctors to manage any emerging symptoms.
Long-term safety monitoring is needed for both medications. While clinical trials have shown them to be effective and generally safe, ongoing observation for potential side effects like fatigue or rare complications like pancreatitis is recommended.
FAQ
Is Wegovy more expensive than Zepbound?
Yes, Wegovy is generally more expensive than Zepbound. Without insurance, Wegovy can cost $1,349.02 per month, while Zepbound is typically priced at around $1,059.87 for a 30-day supply if not covered by insurance. However, a new direct-to-consumer program offered by LillyDirect is bringing prices down significantly for Zepbound.
Can I use Zepbound and Wegovy together for better results?
No, it is not recommended to use Zepbound and Wegovy together. Both medications work in similar ways, and using them simultaneously could increase the risk of side effects without providing additional benefits.
Can I switch from Zepbound to Wegovy for weight loss?
Yes, you can switch from Zepbound to Wegovy if needed. Your healthcare provider can help adjust your dosage and transition between the medications based on your specific weight loss goals and how well you tolerate each drug.
Which weight loss medication is more effective, Zepbound or Wegovy?
Zepbound is generally considered more effective for greater weight loss. Clinical trials have shown that Zepbound can lead to an average weight loss of 21%, compared with Wegovy's average of around 15%. A healthcare provider can help you determine which weight loss medication is right for you based on your individual health profile.
Why do people switch from Wegovy to Zepbound?
Why someone may switch their medication is usually a personal preference. However, if a person is using Wegovy strictly for weight loss and they've been eating healthy and regularly exercising, they may want to talk to their doctor about switching to Zepbound, which has been more effective for weight loss.
Which GLP-1 has the fastest weight loss?
GLP-1 effectiveness can depend on the specific person using it, along with their lifestyle and any pre-existing health conditions. However, in clinical trials, tirzepatide (Mounjaro and Zepbound) was found to be the fastest and most effective weight-loss medication.
Bottom line
Overall, both Zepbound and Wegovy are good for people who are obese or overweight who are interested in losing weight. Zepbound appears more effective for significant weight loss, while Wegovy has added heart health benefits.
In terms of side effects, both drugs can cause nausea, vomiting and gastrointestinal issues, though Zepbound may be better tolerated in some cases.
Zepbound is generally more affordable than Wegovy, especially for people without insurance. But Wegovy can be covered by Medicare and Medicaid if you also have cardiovascular issues.
Consulting with a healthcare professional is important to assess which medication is the best fit.
Article sources
- Eli Lilly and Company, “Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks.” Accessed Sept. 25, 2024.
- Obesity Science and Practice, “Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real‐world setting: A 6‐month retrospective study in the United States (SCOPE).” Accessed Sept. 25, 2024.
- Eli Lilly and Company, “How much should I expect to pay for Zepbound?” Accessed Sept. 25, 2024.
- NovoCare, “What is the list price for Wegovy and will it impact me?” Accessed Sept. 25, 2024.
